Globeflex Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Globeflex Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-335	Closed	-$133K	–	394
2025 Q4	$133K	Buy	+335	New	+$148K	0.02%	349

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Globeflex Capital's ALNY Position: Q1 2026 in Review

Globeflex Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 335 shares — an estimated $133K sold.

Globeflex Capital first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $133K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Globeflex Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Globeflex Capital sold 335 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $133K.
Globeflex Capital first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Globeflex Capital's Alnylam Pharmaceuticals position peaked at $133K in Q4 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.